Marksans Pharma has been issued ‘Restricted GMP Certificate’ from UK MHRA allowing the company to continue manufacturing and marketing of critical products for the UK markets. UK MHRA GMP had inspected Marksans’ Goa plant which was conducted from November 23, 2015 to November 25, 2015.
The restricted GMP status would continue until MHRA’s next inspection. Next re-inspection can be as early as when the Qualified Person EU (QP) certifies site to be inspection ready. Once re-inspected, the same can be reinstated to GMP compliant status. As per MHRA’s assessment, listed products manufactured by Marksans Pharma for the UK market are evaluated to be critical for public health and are allowed continuation of manufacture.
Marksans Pharma is engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.
